Small text
Medium text
Large text
Select Text Size
Send to a Colleague
Print Page

About AMRIX

Consistent Plasma Levels

Multiple-Day Pharmacokinetics of Once-Daily AMRIX

Cyclobenzaprine exposure with AMRIX is less than with cyclobenzaprine IR at steady-state concentrations.12

Multiple-day Pharma Chart

  • At steady-state concentrations, exposure to cyclobenzaprine is 30% less with AMRIX than with cyclobenzaprine IR*
  • With AMRIX, 90% of the steady-state plasma concentration is achieved by Day 4

AMRIX may enhance the effects of alcohol, barbiturates, and other CNS depressants. AMRIX should not be used in elderly patients or in patients with impaired hepatic function.

*The Day 7 Cavg was predicted using single-dose data from pharmacokinetic study 1107 and 7-day data from pharmacokinetic study 1104.